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Safety and Efficacy of Using Nuts to Improve Bowel Health in Hemodialysis 
Patients 
Abstract 
Objective: Constipation is common in patients with end-stage kidney disease. Nondrug strategies to 
manage constipation are challenging because of dietary potassium, phosphate, and fluid restrictions. 
Nuts are a high-fiber food but are excluded from the diet because of the high potassium and phosphate 
content. The aim of this study was to examine the safety and efficacy of using nuts to improve 
constipation in adults undertaking hemodialysis (HD). Design and Methods: Adult patients undertaking 
HD were recruited to this nonrandomized, 10-week repeated measures, within-subject, pragmatic clinical 
trial, conducted in two HD units. The intervention consisted of consumption of 40g of raw almonds daily 
for four weeks, followed by a two-week washout and four-week control period. The primary safety 
outcome measures were change in predialysis serum potassium and phosphate levels. The primary 
efficacy outcome was reduction in constipation, measured using the Bristol Stool Form Scale and 
Palliative Care Outcome Scale (POS-S) renal symptom score. Secondary outcomes included quality of life, 
selected uremic toxins, cognition, gut microbiota profile, and symptom burden. Results: Twenty patients 
completed the trial (median age: 67 [interquartile range: 57.5-77.8] years, 51% male). After controlling for 
dialysis adequacy, anuria, dietary intake, bicarbonate, and parathyroid hormone, there were no statistically 
significant changes in serum potassium (P = 0.21) or phosphate (P = 0.16) associated with daily 
consumption of almonds. However, statistically significant improvements in constipation were seen at 
weeks 2, 3, 4, and 10. There were statistically significant improvements in quality of life (P = 0.030), 
overall symptom burden (P = 0.002), vomiting (P = 0.020), itching (P = 0.006), and skin changes (P = 
0.002). Conclusion: Daily consumption of almonds for four weeks was safe, effective, and well tolerated. 
Improvements in quality of life and symptom burden warrant further research to elucidate potential 
mechanisms. The findings support the potential reinclusion of foods such as nuts into the diet of patients 
who underwent HD. 
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Title: Safety and efficacy of using nuts to improve bowel health in hemodialysis patients 1 
Abstract: 2 
Objective:   3 
Constipation is common in patients with end stage kidney disease (ESKD). Non-drug 4 
strategies to manage constipation are challenging due to dietary potassium, phosphate and 5 
fluid restrictions. Nuts are a high fiber food but are excluded from the diet due to the high 6 
potassium and phosphate content. The aim of this study was to examine the safety and 7 
efficacy of using nuts to improve constipation in adults undertaking hemodialysis (HD). 8 
Design and methods: 9 
Adult patients undertaking HD were recruited to this non-randomised, 10-week repeated 10 
measures, within subject, pragmatic clinical trial, conducted in two HD units. The 11 
intervention period consisted of consumption of 40g raw almonds daily for four weeks, 12 
followed by a two-week washout and four-week control period. The primary safety outcome 13 
measures were change in predialysis serum potassium and phosphate levels, and the primary 14 
efficacy outcome was reduction in constipation, measured using the Bristol Stool Form Scale 15 
and Palliative Care Outcome Scale (POS-S) renal symptom score. Secondary outcomes included 16 
quality of life, selected uremic toxins, cognition, gut microbiota profile, and symptom 17 
burden.  18 
Results:  19 
Twenty patients completed the trial (median age 67 (IQR: 57.5-77.8) years, 51% male). After 1 
controlling for dialysis adequacy, anuria, dietary intake, bicarbonate, and parathyroid 2 
hormone there were no statistically significant changes in serum potassium (p=0.21) or 3 
phosphate (p=0.16) associated with the daily consumption of almonds. However, statistically 4 
significant improvements in constipation were seen at weeks 2, 3, 4 and 10. There were 5 
statistically significant improvements in quality of life (p=0.030), overall symptom burden 6 
(p=0.002), vomiting (p=0.020), itching (p=0.006) and skin changes (p=0.002).  7 
Conclusion: 8 
Daily consumption of almonds for four weeks was found to be safe, effective and well 9 
tolerated. Improvements in quality of life and symptom burden warrant further research to 10 
elucidate potential mechanisms. The findings support the potential re-inclusion of foods such 11 
as nuts into the diet of haemodialysis patients.  12 
Keywords: hemodialysis, nuts, clinical trial, treatment outcome, constipation  13 
Introduction 1 
Abnormal bowel health is common in patients with end stage kidney disease (ESKD), and is 2 
characterised by impaired motility 1, and symptoms such as abdominal pain, indigestion, 3 
reflux and constipation 2. Constipation is estimated to affect more than three quarters of 4 
hemodialysis patients 3. In addition to reduced quality of life (QOL) 4, constipation also 5 
contributes to hyperkalaemia 5, and abdominal discomfort 3. In patients undertaking 6 
peritoneal dialysis, constipation can also cause catheter dislodgment 6,7. Constipation has also 7 
been identified as an outcome of concern by patients and carers 8.  8 
 9 
Poorly designed renal diet prescriptions for patients with ESKD can worsen constipation 9,10 10 
due to overzealous restriction of fruits, vegetables, legumes, nuts and whole grain cereal 11 
products. Typical strategies suggested to manage constipation in healthy populations such as 12 
increasing physical activity, fiber and fluid intake 11 are particularly challenging for  those 13 
with ESKD. This is due partly to the dietary phosphate, fluid and potassium restrictions that 14 
are required.  15 
 16 
In recent years several studies have challenged the paradigm that some nutrient dense foods 17 
that are typically restricted in the renal diet may not need to be. For example, the 18 
bioavailability of phosphorus from plant-based food sources appears to be significantly lower 19 
than the phosphorus in animal derived food sources and phosphate additives 12. Similarly, the 20 
bioavailability of potassium in diets rich in fruit, vegetables and legumes has been shown to 21 
be less than was previously predicted 13,14. Studies such as these, in addition to the recent 22 
evidence of reduced mortality in patients following healthy diet patterns in Chronic Kidney 23 
Disease (CKD) 15,16, have led to suggestions that liberalisation of the renal dietary restrictions 1 
for patients with ESKD may be warranted 17.  2 
 3 
Given the extent of bowel health problems such as constipation, and poor medication 4 
compliance in patients undertaking dialysis 18-20, alternative non-drug strategies to improve 5 
constipation in hemodialysis patients are needed. Nuts may be one potential option to 6 
improve the management of constipation. Nuts are high in protein, fiber, micronutrients and 7 
polyunsaturated fatty acids 21. However, they are also high in potassium and phosphate and as 8 
result, are typically not recommended for inclusion in the diet of a patient who is undertaking 9 
hemodialysis. However, large epidemiological studies have demonstrated that regular nut 10 
consumption is associated with improved laxation in healthy populations 22, as well as 11 
improved gut microbiota profile 23, increased vascular health improved cognition function 24 12 
and reduced mortality 25. A recent meta-analysis reported that a dietary pattern high in fruits, 13 
vegetables, legumes and nuts was associated with a reduced risk of death 15.  14 
 15 
Despite the benefits of nut consumption in the general population 21, whether regular nut 16 
consumption is safe and effective at improving bowel habits in patients undertaking 17 
hemodialysis has not been explored. Given these knowledge gaps, the overall aim of this 18 
study was to determine the safety and efficacy of using a non-drug treatment in the form of 19 
almonds to improve bowel health in adult haemodialysis patients. The hypotheses of this trial 20 
were that consumption of 40g of almonds daily for four weeks is safe and would result in an 21 
improvement in bowel health and specifically a reduction in the prevalence of constipation. 22 
As a secondary outcome, we hypothesised that the intervention would result in improvements 23 
in symptom burden, QOL, uremic toxins, cognition and gut microbiota profile.  24 
Methods 1 
Study design and study population  2 
A non-randomised 10-week repeated measures, within subject, pragmatic clinical trial was 3 
conducted and is reported in accordance with the guidelines for transparent reporting of 4 
studies with non-randomized designs 26, and the checklist for intervention description and 5 
replication 27. The clinical trial was registered with the Australian New Zealand Clinical 6 
Trials Registry (Registration number ACTRN 617000600347p). The joint University of 7 
Wollongong Illawarra Shoalhaven Human Research Ethics Committee approved the study 8 
(HE2017/332) and all study procedures were followed in accordance with the Declaration of 9 
Helsinki.  10 
 11 
The trial setting was two satellite haemodialysis units in a regional health district of New 12 
South Wales, Australia. The trial population consisted of haemodialysis patients attending the 13 
units for therapy. Exclusion criteria were individuals who were pregnant; allergic to almonds; 14 
suffered from dysphagia; or had dental problems that would prohibit consumption of nuts. 15 
Those with a current diagnosis of acute diverticulitis or faecal impaction and those deemed 16 
by nursing or medical staff as unable to follow instructions adequately due to language or 17 
cognitive impairment were also excluded from the trial.  18 
 19 
Recruitment  20 
All hemodialysis patients were approached while undertaking hemodialysis by a member of 21 
the research team. No treating health professionals on the research team assisted with 22 
recruitment. Interested patients provided written informed consent prior to commencing the 1 
trial.  2 
 3 
Study procedures 4 
All assessments were conducted with participants during the second hour of their first thrice 5 
weekly hemodialysis therapy sessions. Following two weeks of pre-intervention assessments, 6 
participants were required to consume the intervention food for a four-week period, followed 7 
by a two-week wash-out period; followed by a subsequent four-week control period.   8 
 9 
Intervention 10 
The intervention consisted of the consumption of 40g raw unsalted almonds with skin daily 11 
for four weeks. This equates to approximately 27 almonds per day. A schematic of the study 12 
is shown in the Supplemental material, Figure 1. Almonds were chosen due to the small 13 
volume required to supply 8g of protein and at least 3 g of fiber. This volume of almonds also 14 
supplied 210mg of phosphate and 318 mg of potassium 28. According to renal diet 15 
specifications this quantity of almonds was considered to be a high phosphate and high 16 
potassium food source 29. Other nuts such as walnuts or macadamias were not considered for 17 
the study as they required daily consumption in excess of 60g which was considered to be a 18 
deterrent to optimal intake. A one-week supply of almonds was provided to all participants at 19 
the start of each trial week. All other components of their usual renal dietary restrictions were 20 
maintained (i.e. the diet continued to be fluid, potassium, phosphate, and sodium restricted). 21 
Participants were instructed to consume the intervention ad libitum but not exceed the 40g 22 
almonds within a 24-hour period. A 40g scoop was provided to all participants to ensure an 23 
accurate and consistent dose was consumed daily. To ensure intervention fidelity, participants 24 
were instructed to return any remaining amounts of almonds each week prior to provision of 1 
the following week’s supply. Residual almond quantities were weighed to ascertain average 2 
consumption of the intervention each week and adherence with the study protocol. During the 3 
wash out and control weeks, participants were instructed to avoid all nut and nut products as 4 
per usual renal diet recommendations and to maintain their usual renal dietary prescription.  5 
 6 
Primary outcome measures  7 
The primary safety outcome measure of the trial was change in predialysis serum potassium 8 
and phosphate levels. All pathology measures were taken on the first dialysis session of each 9 
week following the long dialysis break. Hyperkalaemia was defined as serum potassium ≥ 6 10 
mmol/L. Hyperphosphatemia was defined as serum phosphate ≥ 5.74 mg/dL (or ≥1.85 11 
mmol/L.) 12 
 13 
The primary efficacy measure was change in bowel habits. Three measures of bowel health 14 
were utilised, based on previous research that demonstrated self-report of bowel habit to be 15 
highly variable using different tools 9. Participants rated their bowel habits at baseline, weeks 16 
1-4, 7 and 10 using the Bristol Stool Form Scale with a score of 1 or 2 indicative of 17 
constipation 30. Participants rated their bowel health using a bowel management algorithm 9 18 
which includes questions from the Rome III criteria for the diagnosis of constipation. 19 
Participants also self-rated their bowels using the Patient Outcome Scale- Renal 31. This tool 20 
lists 18 symptoms including weakness, nausea, vomiting, and constipation, and patients rate 21 
the severity and presence of the symptoms.  22 
 23 
Secondary outcome measures 1 
The secondary outcomes of the trial included QOL, serum total and free concentrations of the 2 
uremic toxins p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS), stool microbiota, cognition 3 
and symptom burden. The methods used to measure and collect these outcomes are described 4 
in the Supplemental material.   5 
 6 
Other measures 7 
Nutrition assessment was completed by a trained dietitian using a validated nutrition 8 
assessment tool for use with hemodialysis patients (the Patient Generated Subjective Global 9 
Assessment 32). This assessment was completed at baseline, week 4, 7, 10 of the trial. Dietary 10 
intake during the study was recorded using a three-day food record completed by the patient 11 
(or carer) including one weekend day, dialysis day and non-dialysis day. This was completed 12 
at baseline, weeks 1- 4, 7, 10 of the trial. A diet history interview 33 was also obtained from 13 
the particpants by the same trained dietitian . This information was obtained at baseline, 14 
weeks 4, 7 and 10. Quantitative analysis of dietary intake was undertaken using FoodWorks 15 
(version 9, Xyris Pty Ltd, Highgate Hill, Queensland, Australia), using the AUSNUT 2011-16 
13 food composition database 28. All nutrient data was presented as mean (SD). All 17 
prescribed and over the counter medications, supplements or herbal preparations taken by the 18 
participants to assist with bowel health were recorded at the commencement of each week of 19 
the trial. This was confirmed by having patients bring in pill bottles and/or prescription lists 20 
to the research team for verification.  21 
 22 
Adverse events 23 
An adverse event was defined as any fatal or life-threatening event, or an event posing a 1 
significant hazard, or causing a side effect, and any experiences requiring hospitalisation. 2 
Events were monitored and those occurring during the trial were discussed, documented and 3 
actioned by the clinical team. 4 
  5 
Statistical analyses 6 
Normality of variables was assessed using the Shapiro Wilk test. Data is reported as median 7 
and interquartile range or mean and standard deviation where appropriate. All analyses were 8 
conducted using SPSS (version 25, IMB Corporation, Chicago, IL, USA). General linear 9 
models for repeated measures were tested using a heterogeneous compound symmetry 10 
structure as the variance at each time point were assumed not to be constant. These models 11 
were used to determine the change in serum potassium and phosphate after controlling for 12 
dialysis adequacy, dietary intake of potassium or phosphate, urine output, serum bicarbonate 13 
and serum PTH level. Analysis of the change in uremic toxins after controlling for anuria and 14 
dialysis adequacy was also conducted. The McNemar test was used to determine changes in 15 
the proportion with hyperkalaemia, hyperphosphatemia, adequate bowel habit and laxative 16 
use. The Friedman test on one way ANOVA for repeated measures was used to assess the 17 
change in QOL, uremic toxins, and cognition. Per protocol analyses are reported and a pvalue 18 
of 0.05 was considered statistically significant.  19 
 20 
Results  21 
Thirty two patients were recruited to the study, and 20 participants completed the study 22 
(Figure 2). More than half of the participants were male, with a median age of 67.5 (IQR: 23 
57.5-77.75) years (Table 1). The majority of participants were well nourished according to 24 
the PG-SGA; almost half (45%) were anuric (defined as less than 100mL urine per day), and 1 
almost half (45%) were deemed to be cognitively impaired at baseline on formal assessment. 2 
Multi-morbidity was evident with diabetes, coronary artery and peripheral vascular disease 3 
common. Laxative use was common, with 65% taking laxatives or aperients at baseline. 4 
When compared to evidence based guidelines for the management of hemodialysis patients, 5 
baseline dietary intake was considered to be inadequate for energy, protein, phosphate and 6 
fiber 34. Only 15% of participants reported consuming an adequate intake of dietary fiber 7 
(>25g/day).  8 
 9 
Assessment of safety  10 
Consumption of 40g almonds daily for 4 weeks was not associated with increases in serum 11 
potassium (Table 2, p = 0.21) or serum phosphate (Table 2, p = 0.16) after controlling for 12 
confounders. The proportion of participants who were considered hyperkalemic or 13 
hyperphosphatemic also did not change. There was one adverse event during the trial related 14 
to the intervention which consisted of a patient experiencing a choking episode. No further 15 
medical assistance was required.  16 
  17 
Assessment of efficacy  18 
As shown in Table 2, compared to baseline, there was a significant reduction in the 19 
proportion of participants who reported constipation at weeks 2, 3 and 10 (p = 0.04, p = 0.006 20 
and p = 0.03, respectively). The mean POS renal score for constipation also reduced 21 
significantly during the study (p = 0.02). Laxative use declined significantly between baseline 22 
and week 4 of the intervention from 65% to 20 % (p = 0.02). The mean individual 23 
consumption of almonds during the intervention weeks indicated that adherence to the 1 
intervention was high (Table 2, mean: 89%).  2 
 3 
Secondary outcomes 4 
There was a significant improvement in QOL over the 10 weeks (Table 3). The EQ-5D-5L 5 
index score increased by 0.15 quality-adjusted life-years (QALY) from baseline by week 10 6 
(p = 0.03). There was no change in mean EQ-5D-5L Visual Analogue Scale score, uremic 7 
toxins, or cognition. However, total symptom burden decreased significantly from a mean 8 
score at baseline of 16.7 ± 6.7 to 10.2 ± 6.0 by week 4 and 11.3 ± 9.0 by week 10 (p = 0.002). 9 
Other significant changes in symptom scores occurred for vomiting (p = 0.02), constipation 10 
(p = 0.02), itching (p = 0.006) and skin changes (p = 0.002).  11 
 12 
No differences were observed in faecal microbiota diversity (alpha- or beta-diversity), either 13 
before or following the intervention. The consumption of 40 g daily of almonds over 4 weeks 14 
did not have a measurable effect on faecal microbiota composition (the relative abundance of 15 
specific bacterial taxa) in individuals undertaking hemodialysis.   16 
 17 
Discussion  18 
In this safety and efficacy trial, consumption of 40g almond daily for four weeks was not 19 
associated with harmful elevations of serum potassium or phosphate, or other major adverse 20 
events. The intervention was associated with significant improvements in constipation when 21 
measured using two separate patient reported outcome tools. This trial also saw significant 22 
improvements in QOL and symptoms such as vomiting, itch and dry skin during the 23 
intervention period. This non-drug intervention was also well tolerated by participants, with 1 
excellent adherence to guidelines for consumption of the almonds provided. 2 
 3 
Given the high prevalence of constipation among dialysis patients, safe and effective 4 
management methods are required. This trial suggests that regular nut consumption may be a 5 
potentially effective and safe non-drug alternative or adjunct to traditional methods used to 6 
manage constipation. The effect size of the reduction in constipation between baseline and 7 
week 4 was equivalent to a moderately large effect (Cohen’s d 0.58) and has obvious 8 
practical importance 35. Physiological mechanisms for how nuts may assist with laxation 9 
appear to be more than just the provision of the additional fiber. For example, some authors 10 
suggest the effect on laxation may be related to the presence of large amounts of fermentable 11 
carbohydrates including xylose and galactose in the almond cell wall. These carbohydrates 12 
are known to exert a prebiotic effect 36, providing the substrate for bacterial metabolism that 13 
may confer a benefit for the human host 37. Others suggest that nut digestion induces 14 
remodelling of the gut microbiota 38 via improved butyrate synthesis from the metabolism of 15 
the fiber and polyphenol content.  16 
 17 
In addition to constipation, patients undergoing dialysis commonly report dermatological 18 
symptoms. Mechanisms for the improved skin and reduction in itch (pruritus) reported by 19 
participants in our trial are unknown. Pruritus and xerosis (dry skin) in dialysis patients are 20 
understudied 39, despite pruritus being experienced by almost half of dialysis patients. These 21 
complaints are also associated with reduction in the QOL of dialysis patients 40. Traditionally, 22 
it is thought that xerosis is due to a reduction in the eccrine sweat glands and atrophy of 23 
sebaceous glands 41. It is unclear what role diet may have in these conditions. However, one 24 
may speculate that the improvements in skin and pruritus may be due to the high 1 
monounsaturated fat and vitamin E composition of the almonds. Vitamin E intake has been 2 
associated with skin quality 42, and dietary intake of vitamin E is reduced in individuals with 3 
end stage kidney disease due to a reduction in consumption of rich food sources (nuts, 4 
spinach and wholegrain cereals). Metabolism of vitamin E is also impaired in dialysis 5 
patients 43. Future research to examine the relationship between skin and dietary quality is 6 
warranted.  7 
 8 
This trial adds to the evidence base regarding the high symptom burden and poor QOL 9 
amongst dialysis patients 44, especially those with constipation 4. In this trial, the participants 10 
experienced a range of symptoms in addition to constipation, and the QOL was far below 11 
reported Australian norms (mean index score 0.91 and mean VAS score 78.55) even at 12 
baseline 45. The reasons for the gain of 0.15 of a QALY during the trial period are unknown. 13 
Qualitative research to ascertain why this occurred would have been beneficial and could be 14 
an area for future research.  15 
 16 
There are several strengths to this study. This includes the comprehensive collection of data 17 
regarding potential confounders to the results including in depth dietary data. However, there 18 
are also several obvious limitations. These include the small sample size and short follow up 19 
period. Unlike drug studies, it is difficult to blind participants to whole food interventions, 20 
thus, it is also possible that participants may have been subject to reporting bias. We used 21 
standard tools to assess efficacy outcomes, however, it should be noted that these tools rely 22 
on self-reported changes in bowel habits, which may have also introduced bias. Given the 23 
free-living nature of the participants, this challenge is likely to persist in future studies. We 24 
attempted to minimise inter-individual variation by using a study design where participants 1 
acted as their own controls and undertook the intervention first. This was due to concerns 2 
regarding compliance and potential contamination of the intervention. It was also not 3 
considered appropriate to randomise participants in each site to start on either the intervention 4 
or control period and practical challenges coordinating between sites prevented 5 
randomisation by shift. As a result, we cannot conclude that bias may have influenced the 6 
study findings. It should be noted that many of the improvements seen during the intervention 7 
period (for example frequency of bowel movements, use of laxatives) were mitigated during 8 
the control period, although they remained more favourable than baseline levels. These 9 
results suggest that the intervention was partly responsible, although there may have been 10 
some continued carry-over effects observed during the control period.  11 
 12 
To conclude, this trial offers insights into the utility of including nuts in the diet of 13 
haemodialysis patients to improve bowel health. In addition to being a safe, effective and 14 
well tolerated treatment, this trial also found there were improvements in QOL, and 15 
symptoms such as vomiting, itching and skin changes. Future research into the use of foods 16 
such as nuts to assist with constipation are needed, especially studies with a more robust 17 
study design. Despite no known mechanism, studies exploring the relationship between 18 
dietary changes and skin quality and pruritus will be beneficial for developing potential 19 
treatments. Additional research to elucidate potential mechanisms for these findings is 20 
warranted. Further exploration of dietary patterns in those undertaking dialysis, especially in 21 
those with suboptimal bowel health may also be useful.  22 
 23 
Practical Application 24 
The findings of this study support the potential re-inclusion of foods such as nuts into the diet 1 
of haemodialysis patients.  2 
 3 
 4 
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Supplemental material  1 
Methods 2 
Secondary outcomes: 3 
Overall symptom burden was evaluated using the Patient Outcome Scale- Renal 31 at 4 
baseline, weeks 1- 4, 7, 10 of the study. Reporting of scores is as per the reporting guidelines 5 
of the authors46, with a total score for overall symptom burden ranging from 0 to 68 6 
(indicative of a high symptom burden) . Quality of life was assessed using the EuroQol 5 7 
level Quality of Life Assessment tool (EQ-5D-5L) 47. This tool was completed at baseline, 8 
week 4,7 and 10. Assistance to complete these tools due to poor vision was provided by 9 
members of the research team when required. Analysis of crude scores was undertaken using 10 
the EuroQOL Crosswalk Value Calculator available from https://euroqol.org/eq-5d-11 
instruments/eq-5d-5l-about/valuation-standard-value-sets/crosswalk-index-value-calculator/ 12 
utilising the United Kingdom cross walk scores.  13 
 14 
Serum total and free concentrations of the uremic toxins, p-Cresyl Sulfate and Indoxyl 15 
Sulfate were analysed by ultra-performance liquid chromatography (UPLC) using a 16 
fluorescence detection method developed by the research team 48. Serum samples were stored 17 
at -80°C and then analysed in a single batch. The free fraction of each toxin was defined as a 18 
percentage of total concentration (free serum concentration divided by the total concentration 19 
multiplied by 100). These samples were collected at weeks 1,4, and week 10. 20 
 21 
Serum total and free concentrations of the uremic toxins, p-Cresyl Sulfate (pCS) and Indoxyl 22 
Sulfate (IS) were analysed by ultra-performance liquid chromatography (UPLC) using a 23 
fluorescence detection method developed by the research team 48. Serum samples were stored 24 
at -80°C and then analysed in a single batch. Chromatography was performed with a Waters 25 
Acquity UPLC I class system comprising of a Binary solvent manager, flow through needle 1 
autosampler, fluorescence detector and column manager (Milford MA, USA) and an Acquity 2 
HSS T3 1.8µm (2.1 x 50 mm) column with an Acquity BEH C18 1.7µm VanGuard pre-3 
column (2.1 x 5 mm). Mobile phase A was 50 mmol/L ammonium formate (pH 5.0) and 4 
mobile phase B was 100% acetonitrile. Mobile phase B increased with a linear gradient from 5 
5 to 25 % over 2.1 min, was then maintained isocratically at 70 % for 0.4 min, followed by 6 
0.5 min at 99%. The column was re-equilibrated with initial conditions for 0.5 min. The load-7 
ahead facility within the system was enabled to minimize the run time.  Injection volume was 8 
2 µL for total IS (tIS) and total pCS (tpCS) and 5 µL for fIS and fpCS samples. Column 9 
temperature was maintained at 45oC. We quantified IS, pCS and the internal standard (50 10 
µmol/L 4-ethylphenol) with timed programmed fluorescence detection monitoring at specific 11 
excitation / emission wavelengths (IS: 300/390 nm; pCS: 260/283 nm; 4-ethylphenol: 12 
285/310 nm).   13 
 14 
fpCS and fIS were measured directly, without addition of an internal standard, on 15 
ultrafiltrates prepared at room temperature from 200 µl of serum centrifuged for 10 min at 16 
13000 rpm with a 30000 MWCO filter (Merck, Kilsyth, Australia). tIS and tpCS were 17 
measured after deproteinization of 100 µL serum with 300 µl of ethanol that contained 18 
internal standard (50µmol/L 4-ethylphenol). The mixture was vortexed for 1 min, centrifuged 19 
for 5 min at 13000 rpm and poured into a 2.0 mL tube that contained 200µL H2O and 1mL 20 
dichloromethane. After vortexing for 1 min and centrifuging for 5 min at 13000 rpm, 150 µL 21 
of the aqueous supernatant was transferred to an injection vial. The free fraction of each toxin 22 
was defined as a percentage of total concentration (free serum concentration divided by the 23 
total concentration multiplied by 100). These samples were collected at weeks 1,4, and week 1 
10. 2 
The Montreal Cognitive Assessment (MoCA) Tool 49 was used to screen for cognitive 3 
impairment and changes in cognition during the study. This tool is more sensitive at detecting 4 
mild to moderate impairment than other tools such as the Mini Mental State Examination 50. 5 
The MoCA also comes in a range of more than thirty language versions and a version for 6 
blind participants which we have utilised in our unit previously 51. The MoCA was completed 7 
at week 1, week 4, and week 10 using a different version of the tool each time to limit 8 
learning effects. Assistance to complete these tools due to poor vision was provided by 9 
members of the research team when required. A score of ≤24/30 was used to indicate 10 
cognitive impairment was present 52.  11 
 12 
Faecal samples for gut microbiome analysis were collected from participants using 13 
DNA/RNA shield - Faecal collection tubes (Zymo Research). These samples were collected 14 
at baseline, and the commencement of week 4, week 7 and week 10. Samples were frozen at -15 
80C and then analysed in one batch. Briefly, DNA was extracted using a DNeasy PowerSoil 16 
HTP 96 DNA Isolation kit (Qiagen) _and the 16S rRNA V4 region was used to study the 17 
bacterial community. Amplicon sequencing of the V4 hypervariable region of the bacterial 18 
16S rRNA gene was performed using an Illumina MiSeq platform. The forward and reverse 19 
primers for the V4 region were GTGCCAGCMGCCGCGGTAA (5′ end 515F) and 20 
GGACTACHVGGGTWTCTAAT (3′ end 806R), respectively.  21 
 22 
Sequence data was analysed using QIIME2 2018.2 (https ://qiime 2.org). Raw sequence data 23 
were first demultiplexed and quality filtered using the q2-demux plugin. This was followed 24 
by denoising with DADA2 53 for quality filtering and identification of sequence variants. 1 
Sequence variants were aligned and used to construct a phylogeny with FastTree programme 2 
(using the q2-phylogeny plugin). Core diversity metrics including alpha-diversity (observed 3 
OTUs, Faith’s Phylogenetic Diversity), beta-diversity (weighted and unweighted UniFrac) 4 
and principal coordinate analysis (PCoA) was calculated at a depth of 5508 sequences per 5 
sample. Sequence variants were taxonomically classified against the Silva 132 99% OTUs 6 
reference sequences. 7 
 8 
Confounders  9 
Demographic and clinical information was collected from the electronic medical record and 10 
dialysis flow sheets. Information included age, gender, urine output, laxative use, antibiotic 11 
use, phosphate binder type and dose, potassium binder (Resonium) use, dialysis prescription 12 
including dialyser size and bath strength, and interdialytic weight gain. A weekly pooled 13 
Kt/V was also conducted on each patient. Additional pathology measures were taken on a 14 
weekly basis including urea, creatinine; bicarbonate; calcium; corrected calcium; magnesium; 15 
albumin; C Reactive Protein, liver function tests; and Parathyroid hormone (PTH). 16 
 17 
Table 1. Baseline characteristics of study participants (n = 20) 
Characteristic  Number  
Gender (male) 11 (51) 
Age, years median  67.5 (IQR: 57.5-77.75) 

























Peripheral Vascular Disease  
Coronary Artery Disease 







Cognitive impairment present  
MoCA score  
>24/30 (cognitively normal) 
Between 20-24 (mild-moderate impairment) 
















Dietary intake  
Protein (g/kg) (Ideal: 1.1g/kg) 
Protein (g/day)  
Energy (kJ/kg) (Ideal: 125-146 kJ/kg) 
Energy (kJ/day) 
Sodium (mmol/day) (Ideal: <100 mmol/day) 
Sodium (mg/day) 
Potassium mmol/kg (Ideal: 1 mmol/kg) 
Potassium (mg/day) 
Phosphate (mg/day) 
Fibre (g/day) (Ideal: >25g/day) 













Dialysis adequacy (Kt/V) (mean, sd) 1.5 (0.3) 
  
Legend: Data are mean (SD), median (interquartile range) or n (%). MoCA: Montreal 
Cognitive Assessment (MoCA) Tool. Cognitive Impairment suggested when score <24/30. 
Table 2. Analysis of primary outcomes : safety and efficacy  
 Baseline Week 1 Week 2 Week 3 Week 4 Week 7 Week 10 P value 
Safety outcomes  
Predialysis potassium 
(mmol/L) 
5.43 ± 0.66 5.4 ± 0.6 5.37 ± 0.63 5.34± 0.69 5.45 ± 0.69 5.15 ± 0.96 5.25 ± 0.66 0.21 
Hyperkalemic n (%) 
 
6 (30) 3 (15) 4 (21.1) 4 (20) 4 (20) 4 (20) 4 (20) 0.96 





1.54 ± 0.53 
 
4.90 ±1.58 
1.58 ± 0.51 
 
5.33±1.64 
1.72 ± 0.53 
 
5.39±2.02 
1.74 ± 0.65 
 
5.27±1.89 
1.70 ± 0.61 
 
4.37±1.61 
1.41 ± 0.52 
 
4.90±1.64 
1.58 ± 0.53 
 
0.16 
Hyperphosphatemic n (%) 
 
5 (25) 3 (15) 6 (31.5) 6 (30) 9 (45) 3 (15) 5 (25) 0.37 
Efficacy outcomes  
Constipation rated using  
Bristol Stool Form Scale, n (%)  
 
10 (50.0) 5 (25) 3 (16.6)* 1 (5.3)* 4 (20) 4 (22.2) 2 (13.3)* a 
Constipation according to 
POS-Renal  
1.0 ± 1.0 0.8  ± 1.1 0.5  ± 0.8 0.5  ± 0.8 0.5 ± 0.7 0.6 ± 0.8 0.4 ± 0.7 0.02 











































Frequency of straining n (%) 




























































































Frequency of incomplete 


















































Frequency of sensation that 


















































Laxative use n (%) 
 
13 (65) 4 (21.1) 4 (21.1) 5 (26.3) 5 (20)* 6 (33.3) 6 (37.5) c 
Consumption of intervention 
(g)  
- 36.7 g ± 
4.03 
 
36.7 g  
± 5.06  
 





- - - 
Adherence rate to intervention 
% of 40 g consumed per day 
- 91 92 86 87 - - - 
 
Legend: Reported as mean (sd) or counts (percentage). Serum potassium reported after controlling for dietary potassium intake, serum 
bicarbonate level, urine output and dialysis adequacy. Serum phosphate reported after dietary phosphate, serum PTH level, urine output and 
dialysis adequacy. *=indicates p<0.05 compared to baseline.  
a: Bowel habit assessed using Bristol Stool Form Scale : Compared to baseline: week 2, p=0.04; week 3: p=0.04; Week 10 p=0.04.      
b: Frequency of daily bowel movement compared to baseline: week 2: p=0.03; week 3: p=0.03; week 4: p=0.04 
c: Proportion using laxatives compared to baseline: week 4 : p=0.02 
 
Table 3. Secondary outcomes  
 Baseline Week 4 Week 7 Week 10 P value 
EQ5D5L index score  a 0.60 (0.51-0.74) a 0.72 (0.50-0.87) - a 0.75(0.50-0.86) 0.03 
EQ5D5L VAS score (range 0-100) 62.3  ± 20.2 69.2  ± 22.7 67.8  ±20.9 59.8 ± 24.1 0.27 
PCS (total, umol/ L) (NR: 0.0-38.4) 167.6 ± 100.7 176.4 ± 103.9 - 155. 4 ± 105.1 0.40 
PCS (free, umol/ L) (NR:0.1-2.4) 14.4 ± 14.8 17.6 ± 14.3 - 23.7 ± 18.9 0.18 
IS (total, umol/L) (NR: 0.7-6.3) 136.7 ± 56.9 133.3  ± 54.8 - 111.2  ± 37.9 0.97 
IS (free, umol/L) (NR:0.0-0.2) 25.6  ± 18.4 32.3 ± 20.2  - 38.1 ± 20.4  0.10 
MoCA score (maximum score 30) 24.3 ± 4.3 25.2 ± 3.5 - 23.1 ± 5.1 0.05 
POS-S Renal total score 16.7 ± 6.7 10.2 ± 6.0 11.7 ± 6.6 11.3 ± 9.0 0.002 
POS-S Renal subscores      
Pain  1.1 ± 1.2 0.6 ± 1.0 0.8 ± 1.0 1.2 ± 1.1 0.22 
Shortness of breath 1.2 ± 1.3 0.9 ± 1.2 1.1 ± 1.2 0.9 ± 1.2 0.50 
Weakness  1.8 ± 1.2 1.2 ± 1.2 1.4 ± 1.2 1.4 ± 1.3 0.29 
Nausea 0.8 ± 0.9 0.5 ± 0.8 0.4 ± 0.8 0.7 ± 0.9 0.25 
Vomiting 0.6 ± 0.8  0.2 ± 0.4 0.2 ± 0.5 0.4 ± 0.8 0.02 
Poor appetite 0.5 ± 0.9 0.2 ± 0.4 0.4 ± 0.7 0.3 ± 0.6 0.55 
Constipation  1.0 ± 1.0 0.5 ± 0.7 0.7 ± 0.9 0.4 ± 0.7 0.02 
Mouth problems 0.3  ± 0.7 0.3 ± 0.6 0.5  ± 0.8 0.5  ± 1.0 0.57 
Drowsiness  1.2  ± 1.2 1.0  ± 1.0 1.2  ± 1.1 0.9  ± 1.0 0.70 
Poor mobility 1.2  ± 1.1 1.0  ± 1.1 1.0  ± 0.9 0.8  ± 1.1 0.49 
Itching 1.3  ± 1.0 0.7  ± 0.7 0.7  ±0.9 0.9  ± 1.0 0.006 
Difficulty sleeping  1.4  ± 1.3 1.0  ± 1.2 1.2  ± 1.2 1.0  ± 1.0 0.42 
Restless legs 1.0  ± 1.4 0.8  ± 1.0 0.8  ± 1.0 0.9  ± 1.2 0.78 
Anxiety 1.3  ± 1.4 1.0  ±  1.4 0.8  ± 1.1 0.9  ± 1.1 0.20 
Depression  0.8  ± 1.2 0.7  ± 1.2 0.8  ± 1.2 0.6  ± 1.1 0.51 
Changes in skin  1.3  ± 1.4 0.3  ±  0.6 0.4  ± 0.7 0.4  ± 0.7 0.002 
Diarrhoea 0.1  ± 0.3 0.5  ± 0.8 0.3  ± 0.7 0.1  ± 0.3 0.09 
 
Data reported as mean and standard deviation or a median and interquartile range 
Legend: NR: normal range; EQ-5D-5L: EuroQol 5 level Quality of Life Assessment tool ; VAS: Visual Analogue Scale; PCS: P Cresyl Sulfate; 
IS: Indoxyl Sulfate; MoCA: Montreal Cognitive Assessment score; POS-S Renal: Palliative Care Outcome Scale – Renal 
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